drug_type
RELEVANT_DRUG
intervention_type
Biologic (tri-specific T-cell–engaging antibody)
drug_description
An anti-ROR1/CD3/HSA tri-specific antibody (biologic T-cell engager) that binds ROR1 on tumor cells and CD3 on T cells to activate cytotoxic T-cell killing of ROR1-positive cancers; the anti-HSA arm binds human serum albumin to extend half-life via FcRn recycling.
nci_thesaurus_concept_id
C205353
nci_thesaurus_preferred_term
Anti-ROR1/Anti-CD3/Anti-HSA Trispecific Antibody NM32-2668
nci_thesaurus_definition
A trispecific antibody directed against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1), the T-cell surface antigen CD3 and human serum albumin (HSA), with potential immunostimulating and antineoplastic activities. Upon administration, anti-ROR1/anti-CD3/anti-HSA trispecific antibody NM32-2668 binds to both ROR1 expressed on tumor cells and CD3 expressed on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to ROR1-expressing tumor cells, which results in the CTL-mediated death of ROR1-expressing tumor cells. Anti-ROR1/anti-CD3/anti-HSA trispecific antibody NM32-2668 also binds to HSA, which prolongs the half-life of the agent. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and in many types of hematological malignancies. It plays key roles in tumor cell proliferation and survival.
drug_category
TRISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Not specified
drug_mechanism_of_action
Tri‑specific antibody that binds ROR1 on tumor cells and CD3 on T cells to form an immune synapse and activate cytotoxic T‑cell killing of ROR1‑positive cancers; the anti‑HSA arm binds human serum albumin to extend half‑life via FcRn recycling.
drug_name
NM32-2668
nct_id_drug_ref
NCT06299163